Paul Firuta

Biography

  Mr. Paul Firuta, MBA, has been the Chief Commercial Officer of uniQure N.V. since May 3, 2016. As a key member of the leadership team, Mr. Firuta oversees global commercial and portfolio planning, program management. He is a seasoned biotechnology and pharmaceutical executive. He has 25 years of industry experience successfully commercializing products targeting rare diseases. He has significant and highly relevant commercial experience in the rare genetic disease space, overseeing commercial efforts for Cinryze® for hereditary angioedema (HAE), ideally positions. He served as Chief Commercial Officer of Bio Blast Pharma Ltd. since September 2015. He oversaw in particular, the commercial strategy for Cabaletta (IV trehalose) and leads product candidate set to commence Phase 3 clinical development this year in the United States and Canada. He served as President of US Commercial Operations and Senior Vice President at NPS Pharmaceuticals, Inc. since March 25, 2014 and led the development and execution of the GATTEX sales and marketing plan as well as the commercial launch of NAPTARA. He served as Director of Reimbursement and Managed Care/Vice President of Managed Markets of LEV Pharmaceuticals, Inc. since June 26, 2007. He served as Executive Director of National Accounts and Reimbursement at OraPharma, Inc., a Johnson & Johnson company. Mr. Firuta spent nine years at SmithKline Beecham Pharmaceuticals, where he served as Manager of Business Development and Managed Care. He served as Vice President and General Manager of Americas for ViroPharma, Inc. At ViroPharma, where he was responsible for U.S. commercial operations for CINRYZE and VANCOCIN, representing over $400 million in U.S. revenue. He held commercial leadership positions at SmithKline Beecham Pharmaceuticals (GlaxoSmithKline). Mr. Firuta has a Master of Business Administration from St. Joseph's University and a B.Sc. from King's College, Wilkes-Barre, Pennsylvania.  

Research Interest

 marketing